• Ticker

    Advertisement
DJIA 12,891.75 7.80 0.06%
NASDAQ 2,927.23 11.37 0.39%
S&P 500 1,352.03 2.07 0.15%
Maintenance Notification

Quotes and Portfolios will be down on Sunday February 12, 2012 from 2 AM to 4 AM while we perform maintenance on the site. We apologize for the inconvenience.

BELLUS Health

NASDAQOTH:BLUS.PK

$0.04 $0.00 (0.00%)

Quote as of 1:10 PM EST on 02/09/12

Jump to this page for:

Related Resources

Bellus Health starts selling Vivimind in Canada

11/28/2011 by StockWatch

Bellus Health earns $245,000 in Q3 2011

11/9/2011 by StockWatch

BELLUS Health reports results for third quarter ended September 30, 2011, and provides update on VIVIMIND™ partnerships

11/9/2011 by StockWatch

BELLUS Health reports results for second quarter ended June 30, 2011

8/10/2011 by PR Newswire

Crystal Research Associates Issues Research Report on BELLUS Health Inc. (TOR:BLU)

7/14/2011 by AccessWire

Quebec No. 2 Holdings, LLC: Acquisition of Shares of BELLUS Health Inc.

4/8/2011 by Product Design and Development

Quebec No. 2 Holdings, LLC: Acquisition of Shares of BELLUS Health Inc.

4/8/2011 by StockHouse

Quebec No. 2 Holdings, LLC: Acquisition of Shares of BELLUS Health Inc.

4/8/2011 by Marketwire

BELLUS HEALTH ISSUES SHARES IN FINAL PAYMENT FOR THE EXERCISE OF ITS LEASE TERMINATION OPTION

4/7/2011 by StockWatch

Bellus Health Completes Restructuring Initiatives With Repatriation of Intellectual Property to Canada

4/5/2011 by PharmaLive

Bellus Health signs licence agreement for Viviminda

4/4/2011 by StockWatch

Bellus Health cuts annual burn rate by $1.4-million

3/31/2011 by StockWatch

Bellus Health loses $20.11-million in 2010

2/23/2011 by StockWatch

Bellus Health 'pleased' with phase 1 trial of its Alzheimer's drug; stock soars

1/31/2011 by Canadian Business - Canada

Bellus Health investor Quebec No. 2 Holdings owns 13%

1/20/2011 by StockWatch

Bellus Health Exercises Option to Terminate Lease

1/14/2011 by PharmaLive

BELLUS HEALTH EXERCISES OPTION TO TERMINATE LEASE

1/14/2011 by StockHouse

Bellus Health to sell Cdn subsidiary for $1-million

1/4/2011 by StockWatch

CELTIC THERAPEUTICS AND BELLUS HEALTH INITIATE CONFIRMATORY PHASE III CLINICAL STUDY FOR KIACTA?, A DRUG CANDIDATE FOR THE TREATMENT OF AA AMYLOIDOSIS

12/16/2010 by Biocompare

Crystal Research Associates Issues Updated Report on BELLUS Health Inc.

12/16/2010 by StockHouse

Crystal Research Associates Issues Updated Report on BELLUS Health Inc. (TOR:BLU)

12/16/2010 by AccessWire

Celtic Therapeutics and Bellus Health Initiate Confirmatory Phase III clinical Study for Kiacta, a Drug Candidate for the Treatment of AA Amyloidosis

12/15/2010 by PharmaLive

Market Report, "BELLUS Health Inc - Product Pipeline Review - Q4 2010", published

11/19/2010 by PR-inside - Austria

Bellus Health to cut two-thirds of its employees over the next year

8/9/2010 by Product Design and Development

Bellus Health reports results for second quarter ended June 30, 2010

8/9/2010 by StockHouse

Bellus Health loses $5.81-million in Q2 2010

8/9/2010 by StockWatch

BELLUS Health Inc (BLU) - Financial and Strategic Analysis Review - new company profile and analysis released

7/23/2010 by PR-inside - Austria

Geller Biopharm Successfully Advises BELLUS Health in Its KIACTA(TM) Transaction With Celtic Therapeutics

4/30/2010 by GlobeNewswire

MDVN Falls on Alzheimer's Data - Analyst Blog

3/4/2010 by Zacks Investment Research